---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-023440"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:49:02.782863+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports positive Phase 1 data for LYMPHIR prior to CAR-T in DLBCL

## Summary
- Overall response rate 86% (57% complete response, 29% partial response) at one month in 14 patients.
- One-year progression-free survival 77% (95% CI 43-92%); overall survival 84% (95% CI 49-96%).
- LYMPHIR well-tolerated with no dose-limiting toxicities; no Grade ≥3 LYMPHIR-related immune AEs.
- Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL); supports larger trial.
- Study enrolled high-risk relapsed/refractory DLBCL patients; all proceeded to CAR-T infusion.

## SEC filing metadata
- accession: 0001213900-26-023440
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/0001213900-26-023440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-023440
- JSON: https://secwatch.observer/filing/0001213900-26-023440.json
- Plain text: https://secwatch.observer/filing/0001213900-26-023440.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.